报告题目：Informing therapeutic approaches for p53 mutated cancers
报告人：Gemma Kelly 教授 
主持人：焦会朋 研究员
时   间：2024年3月26日（周二）上午10点
地   点：纳米楼457报告厅
报告人简介：

Associate Professor Gemma Kelly is a Dyson Bequest Fellow and Laboratory Head within the Blood Cells and Blood Cancer Division at WEHI. Originally from the UK, she did her undergraduate studies at Durham University, followed by a PhD investigating virus-associated cancers at the Cancer Research UK (CRUK) Institute at The University of Birmingham. She relocated to Australia in 2009 following the award of a Kay Kendall Leukemia Fund Fellowship. In 2019 she started her own lab in the Blood Cells and Blood Cancer Division at WEHI, headed by Andreas Strasser. Gemma’s team are focused on the interrogation and manipulation of the intrinsic apoptotic pathway for blood cancer therapy. Gemma discovered that MYC-driven lymphomas were highly dependent on pro-survival MCL-1 for survival, and she was a key member of the WEHI team that collaborated with Servier Pharmaceuticals to bring MCL-1 targeting BH3-mimetics into clinical trials for blood cancer patients.  Her team continue to work on identifying resistance factors to BH3-mimetics and have published several papers in this area in leading journals. More recently her research has focused on understanding deregulation of the p53 tumour suppressor pathways in therapy resistant cancers. Her team have generated a number of sophisticated pre-clinical models to study the role of mutant p53 in cancer and to explore new therapeutic approaches for cancers with p53 mutations.